Protagenic Therapeutics appoints Timothy R. Wright as Class II director

Protagenic Therapeutics, Inc.new

Timothy R. Wright appointed to board effective July 18, 2025 as Class II director, term expires at 2026 annual meeting.
Board determined Wright is independent under Nasdaq rules; board now has three independent directors.
Wright is Executive Chairman of Isosceles (since 2019) and President/CEO of BIORG, INC. (since 2023).
He also serves on the board of Agenus Inc. (since 2006) and previously held executive roles at Covidien/Medtronic and Teva.
Wright will receive standard non-employee director compensation as described in the January 2025 proxy statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.